Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

The "Hot Potato" of Mental Health App Regulation: A Critical Case Study of the Australian Policy Arena.

Parker L, Bero L, Gillies D, Raven M, Grundy Q.

Int J Health Policy Manag. 2018 Dec 16;8(3):168-176. doi: 10.15171/ijhpm.2018.117.

2.

Attention deficit hyperactivity disorder late birthdate effect common in both high and low prescribing international jurisdictions: a systematic review.

Whitely M, Raven M, Timimi S, Jureidini J, Phillimore J, Leo J, Moncrieff J, Landman P.

J Child Psychol Psychiatry. 2019 Apr;60(4):380-391. doi: 10.1111/jcpp.12991. Epub 2018 Oct 14. Review.

PMID:
30317644
3.

Mental Health Messages in Prominent Mental Health Apps.

Parker L, Bero L, Gillies D, Raven M, Mintzes B, Jureidini J, Grundy Q.

Ann Fam Med. 2018 Jul;16(4):338-342. doi: 10.1370/afm.2260.

4.

A health app developer's guide to law and policy: a multi-sector policy analysis.

Parker L, Karliychuk T, Gillies D, Mintzes B, Raven M, Grundy Q.

BMC Med Inform Decis Mak. 2017 Oct 2;17(1):141. doi: 10.1186/s12911-017-0535-0.

5.

Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression.

Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, Abi-Jaoude E.

Int J Risk Saf Med. 2016 Sep 17;28(3):143-61. doi: 10.3233/JRS-160728.

6.

Authors' reply to Sasich and Linden.

Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, Abi-Jaoude E.

BMJ. 2015 Oct 14;351:h5412. doi: 10.1136/bmj.h5412. No abstract available.

PMID:
26467813
7.

Analysis of Mortality in Mental Disorders.

Raven M.

JAMA Psychiatry. 2015 Nov;72(11):1150. doi: 10.1001/jamapsychiatry.2015.1362. No abstract available.

PMID:
26398919
8.

Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence.

Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, Abi-Jaoude E.

BMJ. 2015 Sep 16;351:h4320. doi: 10.1136/bmj.h4320.

9.

Health of grey nomads: On the move and under the health sector radar.

Raven M.

Aust J Rural Health. 2016 Jun;24(3):182-7. doi: 10.1111/ajr.12236. Epub 2015 Sep 3. Review.

PMID:
26337254
10.

Two views on the DSM-5: the need for caution in diagnosing and treating mental disorders.

Frances A, Raven M.

Am Fam Physician. 2013 Oct 15;88(8):Online. No abstract available.

11.

Video-based telehealth in Australian primary health care: current use and future potential.

Raven M, Butler C, Bywood P.

Aust J Prim Health. 2013;19(4):283-6. doi: 10.1071/PY13032. Review.

PMID:
24134865
12.

Transparency and accountability in early psychosis intervention research.

Raven M, Jureidini J, Stuart GW.

Aust N Z J Psychiatry. 2013 Jul;47(7):680-1. doi: 10.1177/0004867412457998. No abstract available.

PMID:
23814155
13.

EPPIC mirage: cost-effectiveness of early psychosis intervention.

Raven M.

Aust N Z J Psychiatry. 2013 Jul;47(7):599-601. doi: 10.1177/0004867413484598. No abstract available.

PMID:
23814149
14.

Healthy Kids Check: lack of transparency and misplaced faith in the benefits of screening.

Jureidini J, Raven M.

Aust N Z J Psychiatry. 2012 Oct;46(10):924-7. doi: 10.1177/0004867412460731. No abstract available.

PMID:
23028192
15.

Psychotropic marketing practices and problems: implications for DSM-5.

Raven M, Parry P.

J Nerv Ment Dis. 2012 Jun;200(6):512-6.

PMID:
22833879
16.

Targeted primary care-based mental health services for young Australians.

Raven M.

Med J Aust. 2012 Jun 4;196(10):627. No abstract available.

PMID:
22676872
17.

Guidance offers little in the way of ethics or transparency.

Rogers W, Zutlevics T, Raven M, Jureidini J.

BMJ. 2012 Apr 24;344:e2910. doi: 10.1136/bmj.e2910. No abstract available.

PMID:
22531804
18.

Novel melatonin-based treatments for major depression.

Jureidini J, Raven M.

Lancet. 2012 Jan 21;379(9812):216-7; author reply 217-9. doi: 10.1016/S0140-6736(12)60097-X. No abstract available.

PMID:
22265623
19.

'Prodromal' diagnosis of psychosis: Ethical problems in research and clinical practice.

Raven M, Stuart GW, Jureidini J.

Aust N Z J Psychiatry. 2012 Jan;46(1):64-5. doi: 10.1177/0004867411428917. No abstract available.

PMID:
22247095
20.

Omission of evidence about 5-year outcomes.

Raven M.

Br J Psychiatry. 2011 Mar;198(3):239-40; author reply 240. doi: 10.1192/bjp.198.3.239b. No abstract available.

PMID:
21357884
21.

The increased use of antidepressants has contributed to the worldwide reduction in suicide rates.

Isacsson G, Rich CL, Jureidini J, Raven M.

Br J Psychiatry. 2010 Jun;196(6):429-33. doi: 10.1192/bjp.bp.109.076166.

PMID:
20513850
22.

Does direct-to-consumer advertising of antidepressants lead to a net social benefit?

Jureidini J, Mintzes B, Raven M.

Pharmacoeconomics. 2008;26(7):557-66; discussion 567-8. No abstract available.

PMID:
18563947
23.
24.

Depressed youth, suicidality and antidepressants.

Mansfield PR, Raven MK, Jureidini JN.

Med J Aust. 2005 Sep 5;183(5):275; author reply 276. No abstract available.

PMID:
16247910
25.

Do selective serotonin reuptake inhibitors cause suicide? Suicide rate of 15% in editorial is misleading.

Raven MK.

BMJ. 2005 May 14;330(7500):1150; author reply 1150. No abstract available.

26.

Partnerships between academic psychiatry and the pharmaceutical industry.

Raven M, Rogers W, Jureidini J.

Australas Psychiatry. 2005 Mar;13(1):83-4; author reply 84-6. No abstract available.

PMID:
15777420

Supplemental Content

Loading ...
Support Center